TSR1 (KIAA1401): A Potential Drug Target and Biomarker (G55720)

Target Name: TSR1

NCBI ID: G55720

TSR1

TSR1 (KIAA1401): A Potential Drug Target and Biomarker

Targeting a protein known as TSR1 (KIAA1401) has been identified as a promising strategy to develop new treatments for various diseases. This protein plays a crucial role in the intracellular signaling pathway known as the TGF-β pathway, which is involved in numerous cellular processes, including cell growth, differentiation, and survival. The TGF-β pathway is often disrupted in various diseases, including cancer, neurodegenerative disorders, and developmental defects. Therefore, targeting TSR1 could provide new insights into the pathogenesis of these diseases and the potential for new treatments.

TSR1: Structure and Function

TSR1 is a 21-kDa protein that is expressed in various tissues, including brain, heart, liver, and pancreas. It is composed of an N-terminal transmembrane domain, a well- conserved extracellular domain, and an C-terminal protein domain that contains a unique farnesylated cysteine residue. This cysteine residue is known as a potential drug target and has been implicated in various cellular processes.

The TGF-β pathway is a critical pathway that is involved in the regulation of cellular processes, including cell growth, differentiation, and survival. TGF-β signaling is activated by the binding of the cytoplasmic protein TGF-β1 to the TGF-β receptor, which is a transmembrane protein that plays a critical role in regulating the TGF-β pathway. TGF-β signaling is further regulated by various intracellular factors, including the cytokine environment and the presence of specific inhibitors.

TSR1 is a key component of the TGF-β pathway. It is a negative regulator of the TGF-β pathway, which means that it prevents the activation of the pathway. Specifically, TSR1 interacts with the TGF-β receptor and prevents it from activating the pathway. This interaction between TSR1 and TGF-β1 highlights the potential for TSR1 to be a drug target.

TSR1 has been implicated in various cellular processes, including cell growth, differentiation, and survival. It has been shown to regulate the growth and differentiation of various tissues, including the brain, heart, and liver. TSR1 has also been shown to play a role in the regulation of cell survival, as it has been shown to protect cells from various stressors, including radiation and chemotherapy.

TSR1 has also been implicated in the development and progression of various diseases, including cancer, neurodegenerative disorders, and developmental defects. For example, TSR1 has been shown to be downregulated in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that targeting TSR1 may be an effective strategy for the development of new treatments for these diseases.

TSR1 as a Drug Target

The potential drug targets for TSR1 are numerous. One of the most promising targets is the cysteine residue, which has been shown to play a role in various cellular processes. Cysteine residues are often targeted by small molecules because they are prone to substitution and can be modified to produce pharmacologically active compounds.

One of the most promising small molecules for targeting TSR1 is the inhibitor, KIAA1401. KIAA1401 is a small molecule that is used in the treatment of various neurological disorders, including Alzheimer's disease and Parkinson's disease. It has been shown to cross-talk with TSR1 and prevent its activity as a negative regulator of the TGF-β pathway.

Another potential drug target for TSR1 is the TGF-β receptor, which is a transmembrane protein that plays a critical role in regulating the TGF-β pathway. Activation of the TGF-β pathway is often associated with the development and progression of various diseases, including cancer, neurodegenerative disorders, and developmental defects. Therefore, targeting

Protein Name: TSR1 Ribosome Maturation Factor

Functions: Required during maturation of the 40S ribosomal subunit in the nucleolus

The "TSR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TSR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets